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Abstract
Background—Cotrimoxazole (CTX) prophylaxis is among the key interventions provided to 
HIV-infected individuals in resource-limited settings. We conducted a systematic review of the 
available evidence.
Methods—MEDLINE, Embase, Global Health, CINAHL, SOCA, and African Index Medicus 
(AIM) were used to identify articles relevant to the CTX prophylaxis intervention from 1995 to 
2014. Included articles addressed impact of CTX prophylaxis on the outcomes of mortality, 
morbidity, retention in care, quality of life, and/or prevention of ongoing HIV transmission. We 
rated the quality of evidence in individual articles and assessed the overall quality of the body of 
evidence, the expected impact, and the cost effectiveness (CE) for each outcome.
Results—Of the initial 1418 identified articles, 42 met all inclusion criteria. These included 9 
randomized controlled trials, 26 observational studies, 2 systematic reviews with meta-analysis, 1 
other systematic review, and 4 CE studies. The overall quality of evidence was rated as “good” and 
the expected impact “high” for both mortality and morbidity. The overall quality of evidence from 
the 4 studies addressing retention in care was rated as “poor,” and the expected impact on retention 
was rated as “uncertain.” The 4 assessed CE studies showed that provision of CTX prophylaxis is 
cost effective and sometimes cost saving. No studies addressed impact on quality of life or HIV 
transmission.
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Conclusions—CTX prophylaxis is a cost-effective intervention with expected high impact on 
morbidity and mortality reduction in HIV-infected adults in resource-limited settings. Benefits are 
seen in both pre-antiretroviral therapy and antiretroviral therapy populations.
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INTRODUCTION
Cotrimoxazole (CTX) is a widely used fixed-dose combination of 2 antibiotics, 
sulfamethoxazole and trimetho-prim. CTX was mainly prescribed in the United States and in 
Europe, since the early days of the HIV/AIDS epidemic, to prevent Pneumocystis carinii 
pneumonia. CTX is an affordable medicine, including in resource-constrained contexts 
(commonly costing less than a few US cents per day of treatment).1,2
Although the World Health Organization (WHO) and the Joint United Nations Program on 
HIV/AIDS (UNAIDS) issued the “provisional statement on the use of CTX prophylaxis in 
sub-Saharan Africa in 2000 (Provisional WHO/UNAIDS secretariat recommendations),”3 
until the middle part of the next decade, most countries had not implemented this 
intervention widely. A cross-sectional survey of WHO HIV/AIDS program officers 
conducted in 2007 showed that CTX prophylaxis–related national guidance and policy 
documents were available in 93% of the 41 countries that responded, but only 66% of these 
countries responded that CTX was widely implemented.4 Efforts to implement CTX 
prophylaxis programs were hindered by concerns about the efficacy of CTX prophylaxis and 
by emergence of high levels of anti-sulfonamide resistance.1,5 Evidence on the efficacy of 
CTX prophylaxis and experience with its widespread use have accumulated since 2007.
In 2006, WHO issued guidance addressing CTX prophylaxis for people living with HIV 
(PLHIV) in resource-limited settings (RLS).1 These guidelines addressed CTX prophylaxis 
initiation and discontinuation by age, CD4 count, and WHO clinical stage. WHO 
recommended that, “When the CD4 count is not available, CTX prophylaxis should be 
initiated for adults or adolescents with WHO clinical stage 2, 3, or 4 diseases.” If the CD4 
cell count is available, the guidance recommended “initiation of CTX in PLHIV with CD4 
≤350 cells per microliter regardless of WHO clinical stage and for those with WHO clinical 
stage 3 or 4 irrespective of CD4 count.”1 The WHO also provided a universal option for 
CTX initiation in areas with high HIV prevalence and weak health systems. The June 2013 
WHO consolidated guidelines on the use of antiretroviral drugs for treating and preventing 
HIV infection stated that “CTX prophylaxis should be implemented as an integral 
component of a package of HIV-related services.”6 Recommendations covered use of CTX 
in adults, adolescents, pregnant women, and children for prevention of Pneumocystis 
pneumonia, toxoplasmosis, bacterial infections, and malaria.6
On World AIDS Day 2014, WHO released an update to the 2013 consolidated guidelines, 
stating that, “in settings where malaria and/or severe bacterial infections (SBIs) are highly 
prevalent, adults and pregnant/breastfeeding women should be initiated with CTX 
prophylaxis, regardless of CD4 cell count or WHO stage.”2 Regarding CTX discontinuation, 
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WHO recommended that “CTX prophylaxis may be discontinued in adults (including 
pregnant women) with HIV infection who are clinically stable on ART, with evidence of 
immune recovery and virologic suppression” and that “in settings where malaria and/or SBIs 
are highly prevalent, CTX prophylaxis should be continued regardless of CD4 cell count or 
WHO clinical stage.”2
This review aims at assessing the quality of evidence and the expected impact of CTX 
prophylaxis in HIV-infected adults. We addressed the following outcomes: (1) mortality, (2) 
morbidity, (3) retention in HIV care, (4) quality of life, and (5) prevention of ongoing HIV 
transmission. Cost effectiveness (CE) of CTX prophylaxis was also assessed.
METHODS
We conducted a search of 6 medical literature databases—MEDLINE, Embase, Global 
Health, CINAHL, SOCA, and African Index Medicus (AIM)—to identify articles relevant to 
the CTX prophylaxis intervention published from January 1995 to May 2014. Articles 
eligible for inclusion (1) studied adult PLHIV, (2) were conducted in RLS, and (3) reported 
at least 1 of the 5 outcomes of interest (mortality, morbidity, retention in HIV care, quality of 
life, or prevention of HIV transmission) or costing or CE. A detailed description of the 
search terms applied and the geographic filters used in the literature search can be found in 
the introductory article of this supplement.7 Search terms related specifically to CTX 
prophylaxis included “CTX,” “cotrimoxazole,” “trimethoprim–sulfamethoxazole,” and 
“trimethoprim sulfamethoxazole combination.”
Search outputs (titles and abstracts) were reviewed by the authors to identify potentially 
relevant studies. Articles that seemed to contain data relevant to the intervention and to at 
least one of the outcomes of interest (“eligible” studies) were read in their entirety; those 
that in fact satisfied criteria for inclusion (“included” studies) were abstracted and 
summarized as to study design (eg, randomized control trial, cohort study), population 
studied, comparison group(s), number of participants, and assessment of impact on the 
outcome(s) of interest [expressed as hazard ratios (HR), odds ratios, relative risk (RR), or 
incidence rate ratios (IRR) and the respective 95% confidence intervals (CI) if available].
The quality of evidence from each of the included studies for each outcome of interest was 
rated based on the type of study and other factors, such as the number of study participants 
and internal and external validity of the study data. The overall quality of evidence for each 
study was rated as “strong,” “medium,” or “weak.” Further information on the rating of 
quality of evidence can be found in the abovementioned introductory article.7
Because of the nature of the review and the heterogeneity of study populations, study 
methods, settings, and outcomes, we did not attempt quantitative synthesis of study results 
overall. Rather, the authors grouped the studies by the outcome(s) addressed and rated the 
overall quality of the body of evidence for each outcome as good, fair, or poor.
The expected impact of the intervention by outcome was then assessed based on the 
magnitude of effect demonstrated in individual studies, the quality of the body of evidence, 
and consistency across the studies. Expected impact was rated as high, moderate, low, or 
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uncertain based on criteria agreed on by the reviewers a priori. At least 2 members of the 
review team participated in assigning expected impact ratings for each outcome. Further 
details about the ratings can be found in the introductory article of this supplement.7
CE studies were also assessed. Articles that reported CE were rated separately by a health 
economist and rated as level 1—full economic evaluation (includes CE analysis, cost-utility 
analysis, or cost–benefit analysis); level 2—partial economic evaluations (ie, cost analyses, 
cost-description studies, cost-outcome descriptions); or level 3—randomized trials and 
studies (reporting more limited information, such as estimates of resource use or costs 
associated with the intervention(s) and comparator(s)).7
RESULTS
Of 1418 citations identified using the search terms, 87 contained information on CTX 
prophylaxis that seemed to address at least 1 of the 5 outcomes of interest and/or CE 
(“eligible” studies; Fig. 1). Of these 87 articles, 42 contained information that satisfied the 
criteria for inclusion (“included” studies). Of these 42 studies, 14 individual studies 
addressed exclusively mortality-related outcomes,8–21 7 individual studies focused on 
morbidity,22–28 and 10 individual studies addressed both morbidity and mortality.29–38 Each 
of the 3 included systematic review (SR) and systematic reviews with meta-analysis (SRM) 
addressed mortality,39 morbidity,40 or both outcomes.41 Four studies addressed retention in 
care,42–45 and 4 studies addressed costing and/or CE46–49; none of the 42 studies assessed 
quality of life or HIV transmission as outcome measures. Table S1 (see Supplemental 
Digital Content, http://links.lww.com/QAI/A650) summarizes the study design, sample size, 
key findings, and quality of evidence rating of the 42 included studies.
The 42 “included” studies used different study designs. Nine were randomized control trials 
(RCTs),18,19,23,24,27,29,33,35,38 26 were observational studies 
(OS),8–17,20–22,25,26,28,30–32,34,36,37,42–45 2 were SRM,39,41 1 was another SR,40 and 4 
addressed CE.46–49
Participants included in the studies varied with respect to receipt of antiretroviral therapy 
(ART), WHO clinical stage, history of AIDS-defining illnesses, and CD4 cell count. Of the 
35 individual studies (excluding the SRs and CE studies), 20 (including 4 of the 9 RCTs and 
16 of the 26 OS) included participants either already on or initiating 
ART.8,9,11,13,15,16,20,23–28,31,32,35,36,42,43,45 Fourteen studies (including 5 RCTs and 9 OS) 
included persons who had not received ART (“non-ART” 
participants).10,12,14,17–19,21,29,30,33,34,37,38,44 One study did not report whether patients 
received ART. Of these 35 individual studies, 25 included patients from the general 
population, whereas 10 included patients from specific groups [6 studies included only 
patients diagnosed with tuberculosis (TB)10,12,17,18,21,38 and 4 studies included only 
pregnant women].24,26–28
Of the 4 RCTs that enrolled ART patients, 2 addressed CTX discontinuation23,35 and the 
other 2 compared CTX prophylaxis with intermittent preventive treatment of malaria with 
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either sulfadoxine–pyrimethamine (SP) or mefloquine (MQ) in HIV-infected pregnant 
women.24,27
Five studies included both HIV-infected and HIV-uninfected individuals, and analysis by 
HIV status was conducted in only 2 of these.17,34 The other 3 studies, despite not 
differentiating between HIV-infected and HIV-uninfected persons, contained some relevant 
information. Less than 10% of the enrollees in the study by Grimwade et al12 had a known 
HIV status, and outcome by HIV status was not analyzed. Newman et al28 assessed the 
effect of CTX and intermittent preventive therapy with pyrimethamine–sulfadoxine (IPT-SP) 
in HIV-infected and HIV-uninfected women (SP being the antimalarial that is most widely 
used for malaria prevention in pregnant women50,51), and Bulabula et al22 compared 
pregnant women receiving CTX with an HIV-negative comparator group.
Most studies evaluated a CTX dose of 960 mg daily. Three studies evaluated lower 
doses.10,30,33 In the study by Badri et al30 in South Africa, a dose of 960 mg 3 days per 
week was used initially; thereafter, a dose of 480 mg per day was used. Boeree et al10 in 
Malawi used both 480 and 960 mg doses of CTX (for the latter, mortality outcomes were 
compared with those in 2 historical cohorts). Maynart et al33 compared patients who 
received 480 mg of CTX vs. a placebo.
Summary of Results of Studies in Persons Who Did Not Receive ART
Mortality—Fourteen of the 35 individual studies (CE-related studies, SRM, and SR studies 
excluded) enrolled only patients not on ART; 13 of these, including 5 RCTs18,19,29,33,38 and 
8 OS,10,12,14,17,21,30,34,37 addressed mortality (the 14th study addressed the retention 
outcome).
Evidence From the RCTs (n = 5): The study by Wiktor et al38 among patients with 
TB/HIV in Côte d'Ivoire found a 46% reduction in mortality rate in the group that received 
CTX prophylaxis (95% CI: 23% to 62%; P < 0.001). The study by Anglaret et al29 (also in 
Côte d’Ivoire) showed no decrease in mortality risk, likely as a result of lack of statistical 
power.28
Another RCT by Nunn et al18 (the LUCOT study), which was conducted in Zambia and 
enrolled patients initiating TB treatment, showed a 21% reduction in all-cause mortality in 
persons receiving CTX (HR: 0.79; 95% CI: 0.63 to 0.99; P = 0.04). The mortality benefit 
was most consistent between 6 and 18 months (45% reduction in mortality in participants 
receiving CTX); no benefit was found beyond 18 months. CD4 cell count was not found to 
have an impact on the benefit of CTX prophylaxis. Of note, another RCT by Nunn et al19 
(the TOPAZ study) did not show a significant effect of CTX prophylaxis on mortality 
reduction in HIV-infected postpartum women in Zambia. Investigators suggested that the 
absence of CTX effect, in contrast to the LUCOT study,18 may have been due to 
antibacterial resistance, high loss to follow-up (40%), and the relatively healthy status of the 
women in the study.19
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One RCT by Maynart et al,33 conducted in Senegal, did not show any benefit of the 480 mg 
dose of CTX prophylaxis on mortality or incidence of opportunistic or nonopportunistic 
infections in persons with HIV-1 infection.
Evidence From Observational Studies (n = 8): Eight of the 13 studies addressing 
mortality in patients not on ART were observational. They addressed mortality either alone 
or in combination with morbidity-related outcomes. All 8 OS showed a statistically 
significant benefit of CTX prophylaxis on survival. Of note, 6 of the 8 OS addressed 
mortality exclusively in patients with TB.
Watera et al37 assessed mortality before and after CTX introduction and found a 24% 
decrease in mortality after adjusting for age and CD4 count. Both the studies by Badri et al30 
and Mermin et al34 showed that CTX prophylaxis significantly reduced mortality—an effect 
that was limited to enrollees with CD4 cell counts below the 200 per mictoliter threshold or 
with WHO stage 3 or 4 conditions.
Zachariah et al21 reported significant decreases in deaths in TB/HIV patients receiving CTX 
prophylaxis. Compared with the “non-CTX group,” the “CTX group” showed a 22% 
reduction in mortality (by the end of the anti-TB treatment). A mortality difference was 
observed in the subgroup with smear-negative TB; however, for smear-positive patients, 
neither mortality nor treatment success were significantly different between those receiving 
and those not receiving CTX. It is noteworthy that the study by Zachariah et al,21 is in 
conflict with the study by Wiktor et al,38 from Côte d’Ivoire, in which all participants had 
sputum smear-positive TB at enrollment and in which the association between CTX 
prophylaxis and the reduction in mortality risk was found to be statistically significant [46% 
risk reduction (95% CI: 23 to 62), P < 0.001]. A number of reasons were suggested to 
explain this finding: relatively few patients with smear-positive TB received CTX, the 
smear-positive patients may have been less immunosuppressed than other patients with TB 
(in other studies, CTX had the most significant effect on mortality in those most 
immunosuppressed30), differences in the “timing of administration” of CTX, and possibly 
“differences in patterns of HIV-related disease and rates of CTX resistance.”
Mwaungulu et al17 compared end-of-TB-treatment outcomes, including survival in patients 
with TB registered in 1999 vs. those registered in 2000; 70% of enrollees were HIV 
infected. Patients with either TB or HIV were given CTX prophylaxis in 2000 but not in 
1999. Mortality rates did not differ between the 2 study periods for HIV-negative patients 
but fell in HIV-positive patients from 43% to 24% (the effect was strongest in those who 
were TB smear positive).
Boeree et al10 described an RCT in which 480 or 960 mg of CTX was prescribed to HIV-
infected clients starting TB treatment. Enrollees in this study were followed until the 
completion of their TB treatment. The study aimed at assessing mortality in enrollees 
receiving the 480 mg dose vs. the 960 mg dose. The study also compared mortality with that 
in 2 historical cohorts (which were not on CTX). At TB treatment completion, mortality 
rates were estimated at 15.4% in enrollees who received the 480 mg dose and 14.0% in those 
who received the 960 mg dose, respectively. Mortality rates were lower than in the 2 
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historical cohorts (19.2%; P = 0.10 and 21.0%; P < 0.001, respectively). Grimwade et al12 
found a 29% lower mortality at 6 months in patients with TB (and a 78% HIV prevalence) 
receiving CTX prophylaxis compared with a historical control group (TB patients not 
receiving CTX). Finally, Khoza et al,14 in a study of 234 patients of whom 19% received 
CTX prophylaxis, found that CTX prophylaxis significantly reduced mortality (P = 0.0017).
Morbidity—Of the 13 studies (excluding SRM/SR and those addressing CE) that 
exclusively enrolled non-ART patients, 6 studies addressed morbidity; 3 of these were 
RCTs29,33,38 and 3 were OS.30,34,37
Evidence From the RCTs (n = 3): Two RCTs (Anglaret et al29 and Wiktor et al38) showed 
a significant reduction in morbidity in the CTX group. Anglaret et al reported 43% fewer 
severe events (95% CI: 0.25 to 0.57) in patients on CTX vs. placebo; the benefits were seen 
mainly for bacterial pneumonia, malaria, and isosporosis and were observed at all levels of 
baseline CD4 count. Wiktor et al observed a 43% reduction in hospitalizations (95% CI: 
0.10 to 0.64) in sputum smear-positive TB patients receiving CTX vs. those not receiving 
CTX. In the third RCT, Maynart et al33 showed no benefit of CTX prophylaxis on the 
occurrence of opportunistic or nonopportunistic infections in patients in Senegal. Possible 
explanations for the lack of benefit included the lower dose of CTX used in the Senegal 
study, lower rates of malaria than in Côte d'Ivoire, and differences in bacterial resistance in 
the 2 countries.33
Evidence From Observational Studies (n = 3): Three OS enrolling patients not on ART 
showed that CTX prophylaxis had a protective effect on morbidity-related events. In the 
study by Mermin et al,34 CTX was found to decrease the incidence of malaria by 72%; the 
effect was seen irrespective of age and CD4 cell count; CTX was also associated with a 
reduced rate of diarrhea [0.65 (95% CI), P < 0.0001], also irrespective of age and CD4 cell 
count. In the study by Badri et al,30 enrollees with WHO clinical stages 3 and 4, or a CD4 
cell count below 200 per microliter on CTX demonstrated a 48% reduction of “severe HIV-
related illnesses,” compared with those not on CTX. Watera et al37 reported no change in the 
frequencies of febrile and other morbidity events after CTX prophylaxis was introduced. 
They, however, showed a reduction in malaria incidence (estimated at 0.31; 95% CI: 0.13 to 
0.72).
Summary of Results of Studies in Persons Who Received ART
Mortality—Eleven articles that addressed mortality in patients on ART were assessed, 
including 1 RCT,35 9 OS,9,11,13,15,16,20,31,32,36 and 1 SRM.39 Patients enrolled in these 
studies initiated CTX prophylaxis before, at the same time as, or after ART initiation.
Evidence From the RCT (n = 1): The single RCT addressing CTX prophylaxis and 
mortality among persons on ART did so in the context of discontinuing CTX in persons 
stable on ART. Polyak et al35 assessed a “composite” primary end-point of morbidity and 
mortality among ART patients who discontinued vs. those who continued CTX in Kenya. 
This combined morbidity/ mortality end-point was significantly more frequent in the CTX 
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discontinuation arm than in the continuation arm (IRR = 2.27; 95% CI: 1.52 to 3.38; P < 
0.001) and was mainly driven by malaria morbidity.
Evidence From Observational Studies (n = 9): In a study by Alemu and Sebastian,8 
multivariate analysis showed that CTX prophylaxis begun at or before ART initiation was 
significantly associated with 2-year survival. The studies by Amuron et al,9 Fairall et al,11 
and Lowrance et al15 all showed that not being on CTX prophylaxis was independently 
associated with increased mortality. In the study by Van Oosterhout et al,20 not receiving 
CTX prophylaxis was an independent risk factor for mortality at 14 and 26 weeks in the 
logistic regression analysis. Walker et al36 reported a 35% reduction in mortality associated 
with CTX prophylaxis. The benefit was highest in the first 12 weeks of follow-up (59%), 
maintained from 12 to 72 weeks (44%), and waned beyond the 72 weeks of follow-up 0.96, 
0.63–1.45; heterogeneity P = 0.02 no statistically significant association was found between 
mortality and the CD4 cell count. Madec et al found that the protective effect of CTX was 
limited to patients with CD4 cell count <200 cells per microliter.33
Hoffmann et al13 found a 36% reduction in mortality (HR: 0.64; 95 CI: 0.57 to 0.72; P < 
0.001) associated with CTX. In a later study, Hoffman et al31 found a 52% reduction in 
mortality (effect size: 0.48; 95% CI: 0.21 to 1.1; P = 0.09). The limited number of deaths 
reported in the latter study contributed to the non-statistically significant mortality reduction.
Lim et al32 examined the effect of “Pneumocystis Pneumonia (PCP) prophylaxis” on the 
occurrence PCP and on survival among the patients enrolled in the “TREAT Asia HIV 
Observational Database (TAHOD).” Enrollees not on prophylaxis were significantly less 
likely to survive compared with those who were on prophylaxis (incident rate ratio for death 
estimated at 10.8, P < 0.001).
Evidence From Systematic Reviews (n = 1): A SRM conducted by Suthar et al39 evaluated 
the effect of CTX prophylaxis on mortality among participants on ART and reported a 
decreased death rate in persons on CTX as compared with those not on CTX (“summary 
estimate”: 0.42; 95% CI: 0.29 to 0.61). Of note, only 2 of the 8 studies included in this SR 
followed participants for more than an average of 13 months. Examining the association 
between CTX prophylaxis and baseline CD4 cell count was not possible as, in most of the 
studies included in the meta-analysis, enrollees were started on ART based on a CD4 cell 
count below 200 cells per microliter. However, Hoffmann et al13 (cited above and included 
in the meta-analysis) demonstrated that enrollees were more likely to survive when they 
received CTX prophylaxis at ART initiation (a 36% reduction in mortality). No statistically 
significant association was found between CTX prophylaxis and survival in the subgroup of 
persons with both CD4 cell count above 200 cells per microliter and WHO stage 1 or 2.13
Morbidity—Of the 10 studies that addressed morbidity among patients on ART, 4 were 
RCTs (including 2 studies that enrolled pregnant women and 2 that addressed CTX 
discontinuation).23,24,27,35 The remaining 6 studies were observational.
RCTs Enrolling Pregnant Women (n = 2): The study by Denoeud-Ndam et al24 was 
conducted in Benin where Plasmodium falciparum transmission is considered to be “intense 
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and perennial,” with recrudescence during the rainy season. The authors enrolled HIV-
infected pregnant women with CD4 counts of <350 per microliter who were randomized to 
receive CTX alone or in combination with MQ-IPTp. CTX alone was non-inferior to the 
combination in preventing malaria. However, polymerase chain reaction–detected placental 
parasitemia was reduced in the CTX + MQ group (0/105 vs. 5/103; P = 0.03).24 A second 
RCT by Klement et al27 examined the effect of CTX prophylaxis, as compared with that of 
IPTp-SP, on malaria prevention in HIV-infected pregnant women in a P. falciparum–endemic 
West African country (Togo).27 In this study, 75.4% of women who received CTX 
prophylaxis did not develop malaria as compared with 84.7% of women who received IPTp-
SP—a difference of 9.3% (95% CI: 20.53 to 19.1), not meeting the predefined “non-
inferiority” criterion. The authors did not conclude that CTX was inferior to IPTp-SP 
regarding malaria-free survival (the study was designed to assess “noninferiority”), but the 
difference in point estimates of malaria-free rates suggests that CTX could potentially be 
inferior to IPTp-SP. However, HIV-infected pregnant women on CTX prophylaxis are more 
likely to remain malaria-free than those who are not receiving any antimalarial drug for 
prophylaxis. Daily CTX was also demonstrated to be safe and at least similarly effective at 
reducing parasitemia or placental malaria and adverse birth outcomes.27
RCTs Addressing CTX Discontinuation (n = 2): Campbell et al23 showed, in an 
evaluation of CTX discontinuation among patients receiving ART, that discontinuation of 
CTX prophylaxis, as compared with its continuation, resulted in an increased risk for 
malaria (RR = 32.5; 95% CI: 8.6 to 275.0; P < 0.001) and diarrhea (RR = 1.8; 95% CI: 1.3 
to 2.4; P < 0.001). This study was stopped at the recommendation of the Data Safety 
Monitoring Board after just 4 months, which prevented investigators from evaluating the 
duration of the increased risk for malaria. A longer follow-up duration would have helped 
determine if the increased incidence of malaria was due to a short-lived rebound effect after 
discontinuation CTX.23 Of note, “rebound effects” have been suggested to reflect a short-
term impairment of protective immunity as a result of the suppressive effect of malaria 
medications,52–54 including “persisting asymptomatic and polyclonal P. falciparum 
infections” that occur in the absence of prophylaxis.54–56
The recent RCT by Polyak et al,35 a non-blinded noninferiority randomized clinical trial of 
CTX prophylaxis cessation vs. continuation among HIV-infected adults who had been on 
ART for >18 months and had CD4 >350 per microliter, found that patients who discontinued 
CTX had an increased incidence of clinical malaria but not pneumonia or diarrhea compared 
with those who continued CTX.35 There were 34 cases of malaria, of which 33 occurred in 
the CTX discontinuation arm (IRR = 33.02; 95% CI: 4.52 to 241.02; P = 0.001). The 
significantly higher combined morbidity/mortality in the CTX discontinuation arm (IRR = 
2.27; 95% CI: 1.52 to 3.38; P < 0.001) was driven by malaria morbidity.
Evidence From Observational Studies (n = 6): In the study by Walker et al,36 CTX 
prophylaxis reduced the frequency of malaria (odds ratio: 0.74; 95% CI: 0.63 to 0.88; P = 
0.0005); the effect was maintained beyond 72 weeks. It is noteworthy that trials in ART-
naive participants have typically had little follow-up beyond 72 weeks.
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In the study by Dow et al,25 protection against malaria was similar in HIV-infected pregnant 
women who received CTX prophylaxis compared with those who received IPTp-SP. In the 
study by Kapito-Tembo et al,26 CTX prophylaxis led to a higher protection against malaria 
parasitemia compared with IPTp-SP.
Newman et al28 reported that, when compared with HIV-uninfected women on IPTp-SP, 
CTX prophylaxis was not found to have an effect on the risk for placental malaria in HIV-
infected women.
Because of some evidence of in vitro activity of CTX against Mycobacterium tuberculosis, 
Hoffman et al31 addressed the effect of CTX on TB incidence and “TB diagnostic yield” in a 
cohort of HIV-infected adults living in a high TB prevalence region. Enrollees who received 
CTX prophylaxis were found to be at an increased risk for TB (HR estimated at 1.7; 95% 
CI: 1.2 to 2.2). However, this association was believed to be due to confounding; no effect of 
CTX prophylaxis was found when analysis was based on data exclusively from laboratory-
confirmed TB cases (HR estimated at: 0.97; 95% CI: 0.39 to 2.4).31 Finally, Lim et al32 
showed no statistically significant association between CTX prophylaxis and the risk for 
PCP.
Retention in Care (n = 4)
All 4 studies that met criteria for inclusion in our review for this outcome were 
observational. All showed, with a variable level of quality of evidence, that CTX prophylaxis 
is either associated with a higher retention in care or a higher likelihood of being started on 
ART within 1 year of the initial CD4 testing.
Kohler et al44 found a statistically significant association (P < 0.001) between CTX 
prophylaxis and 12-month retention in care among patients not yet eligible for ART (84%) 
as compared with those who did not receive CTX prophylaxis (63%). Enhanced patient 
follow-up, including the use of phone calls when CTX was not picked up on time, was a 
potentially confounding factor.44 In a study by Auld et al42 to evaluate outcomes of patients 
who initiated ART between 2004 and 2007 in Mozambique, “lack of CTX prescription” was 
a “predictor of attrition” (adjusted HR = 1.4; 95% CI: 1.0 to 1.8).
Clouse et al43 reported that the proportions of those who went on to initiate ART within 1 
year of initial CD4 testing were 96.4% and 9.1% for those who initiated CTX prophylaxis 
and those who did not, respectively.43 Finally, Msellati et al45 has shown, in a multivariate 
analysis, that not being enrolled in the “Drug Access Initiative” and not being on ART were 
both related, among several factors, to not being on CTX prophylaxis.45
Quality of Evidence and the Expected Impact on Mortality, Morbidity, and Retention in Care
Of the 26 studies (excluding the 4 CE studies) that addressed mortality, the quality of 
evidence was rated as “strong” for 3 studies,29,35,38 “medium” for 22 
studies,8,10–21,30–34,36,37,39,41 and “weak” for 1 study (Table 1; see also Table S1, 
Supplemental Digital Content, http://links.lww.com/QAI/A650).9 The overall quality of 
evidence in these studies for the mortality outcome was rated as “good.” The expected 
impact of CTX prophylaxis on mortality was rated as “high.” Of the 21 studies that 
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addressed morbidity (excluding the 2 CE studies), the quality of evidence was rated as 
“strong” for 6 studies,23,24,27,29,35,38 “medium” for 12 studies,25,26,28,30–34,36,37,40,41 and 
“weak” for 1 study.22 The overall quality of evidence for the morbidity outcome was rated as 
“good.” The expected impact of CTX prophylaxis on morbidity was rated as “high.” For the 
retention in care outcome, the quality of evidence was rated as “medium” for 2 studies42,44 
and “weak” for 2 studies43,45. The overall quality of evidence for this outcome was rated as 
“poor.” The expected impact of CTX prophylaxis on retention in care was rated as 
“uncertain.”
Cost Effectiveness (n = 4)
Four studies that addressed the CE of CTX prophylaxis were evaluated; all were rated level 
1 (full economic evaluation: cost-effectiveness analysis).
Using a “simulation model-based study” of HIV disease, based on country-specific data 
from Côte d’Ivoire, Yazdanpanah et al49 assessed the CE of alternative strategies for 
initiation of CTX. The investigators concluded that CTX prophylaxis is “most effective” and 
“reasonably cost-effective” when initiated at WHO stage 2 (vs. stage 3 or 4). For instance, 
the “incremental CE” of CTX initiation at stage 2 disease was US $150 per year of life 
gained, and “lifetime costs” were increased by US $60, when compared with the “no-
prophylaxis” option. Strategies including CD4 cell count testing were found to be more 
costly and less effective.49
Using a computer-based simulation model, Goldie et al47 assessed the potential long-term 
“clinical and economic impact” associated with each of 4 different strategies—ART, ART 
and CTX prophylaxis, CTX prophylaxis, or “no-treatment.” Strategies that included CTX 
prophylaxis were always found to be more cost-effective than those that used ART alone. 
The authors concluded that ART and CTX is a more attractive strategy, particularly in 
resource-constrained settings, regardless of whether ART initiation is determined using 
clinical or immuno-logical criteria. Findings included an “incremental cost per year of life 
gained” estimated at $240 for the “CTX-alone” strategy.
In a study that modeled the CE of daily CTX prophylaxis from a prospective cohort study in 
a rural area in Uganda in the pre-ART era, Pitter et al48 showed that providing “universal 
CTX prophylaxis” (CTX initiated regardless of CD4 cell count and WHO clinical stage), as 
compared with the “non-CTX prophylaxis” option, resulted in 7.3 additional life-years and 
7.6 additional disability adjusted life-years per 100 person-years, respectively, at a “gross 
cost” (before deducting “medical care-related costs”) of $11.88 per person-year and “a net 
saving” estimated at $2.50 per person-year.
Finally, Abimbola and Marston46 used a “decision analytic model” to estimate the 
incremental cost, deaths averted, and incremental CE ratio of CTX prophylaxis in improving 
survival during the first 6 months of ART. “Full coverage” of the CTX scenario, compared 
with the “base case” scenario, resulted in an estimated “incremental cost” of $3.29 per 
patient ($163.65 vs. $160.36). “Full coverage” was also found to be associated with a 
reduction in the number of deaths, particularly during the first 6 months, compared with the 
“base case” of ART alone (22 deaths averted). The study concluded that CTX prophylaxis 
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was a cost-effective strategy to improve survival among severely immunocompromised 
newly registered HIV-infected persons starting on ART.
DISCUSSION
Our review revealed significant heterogeneity in studies in terms of design, participant 
numbers, study population, duration of follow-up, implementation setting, timing of CTX 
initiation, and end-point definitions (Table 2; see also Table S1, Supplemental Digital 
Content, http://links.lww.com/QAI/A650). Despite this heterogeneity, the impact of CTX 
prophylaxis on mortality, AIDS-related illnesses, and malaria was remarkably consistent in 
both persons receiving and not receiving ART. Evidence for impact is strongest for patients 
with CD4 <350 cells per microliter or with WHO clinical stage 3 or 4 disease. In fact, data 
showing a mortality benefit are scarce for patients with higher CD4 counts. However, 
morbidity benefits, especially in preventing malaria, are consistently seen in persons with 
CD4 counts >350 cells per microliter.
Data on the durability of the benefit of CTX are somewhat limited. Walker et al36 
demonstrated a mortality benefit in ART patients receiving CTX up to 72 weeks after 
starting ART. However, the same study shows a reduction in the risk for new or recurrent 
WHO clinical stage 3 or 4 disease events and in the risk for malaria for up to 5 years. 
Consistent with these observations, the 2 studies addressing CTX discontinuation in persons 
on ART (both RCTs and both in malaria-endemic areas) demonstrated that discontinuation 
of CTX results in an increased risk for malaria.23,35
Limitations
This review provided useful information, but there were several limitations. Most studies 
were observational and therefore potentially confounded by other factors that may influence 
mortality and morbidity outcomes. Definitions of morbidity-related end-points varied across 
reviewed studies (Table 2). Some studies included both HIV-infected and HIV-uninfected 
persons, making the impact of CTX in HIV-infected persons difficult to ascertain. Several 
studies in HIV-infected pregnant women involved comparisons between CTX and other 
intermittent preventive treatment regimens to prevent malaria, making it difficult to assess 
the protective effect of CTX alone.
Research Gaps
Consistent with WHO recommendations, the benefit of CTX seems to persist in persons who 
are stable on ART in areas in which malaria and SBIs are common. However, more precise 
benchmarks for defining these thresholds, and therefore for determining when CTX might 
be discontinued, especially in malaria non-endemic areas, are unknown. The mechanism by 
which malaria occurs in persons discontinuing CTX merits more research; it is possible that 
waning immunity to malaria in those receiving CTX is time limited once the drug is 
discontinued. CTX seems to confer benefit against bacterial infections for which local 
antimicrobial resistance seems common; this is also true for protection against malaria in 
areas where resistance to SP is common. What is the mechanism of benefit, and is it possible 
that it will diminish with time? For HIV-infected pregnant women, CTX seems to offer 
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comparable antimalarial benefit with IPTp, but uncertainties remain whether this protection 
is optimal and whether chemoprophylaxis against malaria should be supplemented in some 
way for HIV-infected pregnant women in malaria-endemic areas.
Programmatic Considerations
Nearly all countries have guidelines for the use of CTX, either stand-alone or incorporated 
into ARV treatment guidelines, and knowledge of the importance of CTX for HIV-infected 
persons has become essentially universal in recent years. However, implementation remains 
suboptimal, frequently because of drug stock-outs or diversion of existing stocks to treat 
bacterial infections in HIV-infected and non–HIV-infected patients. Therefore, in addition to 
continued guidance and training of healthcare providers concerning the importance of CTX, 
supply chains need to be strengthened to assure patient access to this drug. Considerations 
should be given at the health-facility level to maintain separate supplies of CTX for 
prophylaxis for HIV-infected persons. Monitoring and evaluation of implementation of CTX 
prophylaxis should be strengthened, so that data on the proportion of persons eligible for the 
drug who are in fact receiving it are available; quality improvement programs should be in 
place to address program deficiencies.
CONCLUSIONS
Our review emphasizes the existence of good quality consistent evidence of a protective 
effect of CTX on mortality and morbidity in HIV-infected adults in RLS, especially in sub-
Saharan African settings. Evidence for mortality benefit is strongest in those with the lowest 
CD4 counts, but morbidity benefits are found in those with higher CD4 counts, especially in 
malaria-endemic areas. Questions remain on the durability of benefit, the appropriate time to 
discontinue prophylaxis in malaria–non-endemic areas, and whether CTX alone offers 
sufficient protection against malaria in HIV-infected pregnant women.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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TABLE 1
Summary of the Body of the Evidence From All Studies by Outcome
Overall Quality of 
Evidence
Impact of the 
Intervention
Evidence From Economic 
Evaluation




































Good High 4 Four level 1 “good-
quality” studies 
have shown that 
CTX prophylaxis 
intervention is CE 
compared with “no-
intervention.” 
Furthermore, it is a 
CE intervention 





Of the 7 assessed RCTs, 6 
included non-ART 
participants.10,18,19,29,33,38 One 
study included patients on ART35
Of the 7 assessed RCTs, 2 
enrolled exclusively TB 
participants10,38
Most of participants included in 
the 7 RCTs had available baseline 
CD4 counts
Of the 17 assessed OS, 10 
included participants on 
ART8,9,11,13,15,16,20,31,32,36
Of the 3 assessed SRM/SR, 1 
included studies with participants 
on ART only,39 1 included both 
studies with ART and non-ART 
participants,40 and 1 included 














showed however a 
modest gain in 
DALYS with the 
CTX prophylaxis 








Of the 7 assessed RCTs, 4 
included participants on 
ART23,24,27,35
Of the 10 assessed OS, 3 included 
patients not on ART30,34,37, and 1 
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Overall Quality of 
Evidence
Impact of the 
Intervention
Evidence From Economic 
Evaluation

































did not report the ART status of 
the participants22
Only 1 SRM included exclusively 
participants not on ART41; All 3 
studies included in the SRM were 
RCTs29,33,38
Of the 21 assessed, 6 studies 
included exclusively TB 
patients10,12,17,18,21,38
Retention in care 4 Poor Uncertain 0 NA Of the 4 assessed studies 3 
included participants on or 
initiating ART.42,43,45
Of the 4 assessed studies 1 
enrolled patients not on ART44
Assessment of the expected impact of the intervention was based on published evidence. Additional considerations that would inform 
implementation decisions would have to take into account the CE information and country-specific contextual considerations.
ART, antiretroviral therapy; CE, cost-effectiveness; CTX, cotrimoxazole; DALY, disability adjusted life years; OS, observational study; TB, 
tuberculosis; RCT, randomized controlled trial; SR, systematic review; SRM, systematic review meta-analysis.
*
The expected impact of the intervention was rated as high = intervention expected to have a high impact on the outcome; moderate = likely to 
have a moderate impact on the outcome; low = intervention expected to have a low impact on the outcome; or uncertain = available information is 
not adequate to assess estimated impact on the outcome.
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TABLE 2
FU Durations, Morbidity Definitions, and Enrollment in Study Criteria
Citation FU Duration Morbidity Definition (When 
Applicable)
Criteria for Enrollment in Study
Abimbola and Marston46 CE study CE study CE study
Alemu and Sebastian8 Mean = 2 yrs NA Aged ≥15 yrs and receiving ART on at least 2 clinic 
visit
Amuron et al9 FU duration: 3.5 yrs NA Aged 18 yrs or older
Anglaret et al29 Mean = 0.9 yrs Morbidity-related events that 
could be prevented by CTX, 
including bacterial infections 
and malaria
Aged 18 yrs or older with HIV-1 or (HIV-1 and 
HIV-2) infection. WHO stages 2 or 3
Auld et al42 Median = 1.3 yrs NA WHO stage 4, stage 3 disease and CD4 counts <350/
μL or stage 1 or 2 and CD4 cell counts <200/μL
Badri et al30 Median = 1.15 yrs “Newly diagnosed severe 
HIV-related illnesses”: 
“AIDS-defining illnesses,” or 
WHO stage 4 bacterial 
infections and PTB
HIV-infected patients in South Africa (WHO clinical 
stages 2–4 or CD4 count <500 cells/μL or total 
lymphocyte count equivalent). Patients using ART 
were excluded
Boeree et al10 FU duration = 0.7 yrs NA HIV-positive new smear-positive PTB patients
Bulabula et al22 CS study (duration of 
recruitment: 0.3 yrs)
Malaria prevalence 
(parasitemia): positive smear 
for plasmodia
HIV-infected and HIV-noninfected individuals
Campbell et al23 FU duration: 0.3 yrs Malaria: “smear-positive 
episode of fever.” Diarrhea: “3 
or more loose or watery stools 
reported by the enrollee, in a 
given 24-hr duration since the 
previous visit”
Enrollees through their fourth year of follow-up, 
with CD4 cell counts >200 cells/μL: “continue” or 
“discontinue” CTX
Clouse et al43 FU duration: 1 yr NA Newly enrolled in the program, no history of 
previous ART uptake, pregnancy excluded, aged 18 
yrs or older, with first CD4 count test performed in 
2010; initial CD4 cell count <200 cells/μL
Denoeud-Ndam et al24 FU duration: from 16 to 
28 wk gestation until 
birth
For malaria diagnosis: blood 
smear (thin and thick)
HIV-infection, pregnancy, women aged 18 yrs or 
older
Pregnancy: 16-28 wk
Dow et al25 FU duration: 0.54 yrs, 
since study second 
antenatal visit, to assess 
probability of malaria-
free survival
Malaria was defined as “the 
first episode after the second 
prenatal visit” and was 
diagnosed by a positive blood 
smear from a woman 
presenting with malaria 
symptoms (including fever 
>38°C, sweats, chills, malaise, 
headache, or pallor)
HIV-infection and pregnancy
No history of ART uptake
Aged 14 yrs or older
30 wk of gestation or less
Hemoglobin >7 g/dL, CD4 cell count ≥250 cells/μL
Fairall et al11 Median = 0.3 NA Aged 16 yrs or older who had been in contact with 
the program at least twice
Goldie et al47 CE study CE study CE study
Grimwade and Swingler41 SRM NA SRM
Grimwade et al12 FU duration: 0.66 yrs NA Active TB, irrespective of HIV status
Hoffmann et al31 Person-years of FU: 
4875
Routine symptom-based 
assessment for TB with 
laboratory investigations as 
indicated
Aged 18 yrs and older with CD4 counts < 350 cells/
μL
Hoffmann et al13 Mean = 0.8 NA Patients starting ART
Kapito-Tembo et al26 CSS: duration of 
recruitment: 4 yrs
“Microscopic malaria 
infection”: parasites found on 
HIV infection and pregnancy, aged 15 yrs or older, 
over 34 wk of gestation
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microscopy “malaria PCR-
detected malaria”: “positive 
PCR” for malaria, irrespective 
of the microscopy result
Khoza et al14 Not reported NA HIV-infected patients admitted at a major teaching 
hospital
Klement et al27 FU duration: from 14 to 
28 wk gestation until 
birth
Malaria: positive test, 1 
symptom or more, including 
fever
HIV 1 infection, pregnancy, <28 wk of gestation, 
CD4 cell count ≥200 cells/μL, hemoglobin ≥7 g/dL
Kohler et al44 FU duration: 1 yr NA ART ineligible patients before and after free CTX 
provision
Lim et al32 FU duration: 0.8 yrs “AIDS-defining illness” 
definition based on the “1993 
Centers for Disease Control 
and Prevention (CDC)”
Patients included in the TREAT Asia HIV 
Observational Database (TAHOD)
Lowrance et al15 FU duration: 0.5 yrs NA Participants aged 15 yrs or older, WHO stage 3 or 4 
or a CD4 count cell ≤200 cells/μL
Madec et al16 Median = 1.08 Enrollees aged 13 yrs or older, WHO stage 4 or a 
CD4 count cell ,200 cells/μL
Manyando et al40 SR (see individual 
studies)
SR (see individual studies) SR (see individual studies)
Maynart et al33 Mean = 0.7 Infections (including bacterial 
pneumonia, PCP, enteritis)
HIV 1 (HIV 1 and HIV 2), aged 15 yrs or older, with 
CD4 count below 400 copies/μL, no progressive 
infection
Mermin et al34 FU duration: 1 yr Malaria: fever and a positive 
blood smear; diarrhea: “3 or 
more loose or watery stools in 
a 24-hr period”
HIV-1 infected individuals and their HIV-negative 
household members
Msellati et al45 CS: duration of 
recruitment: 0.3 yrs
NA HIV-infected adult patients
Mwaungulu et al17 FU duration: 1.5 yrs NA TB patients (PTB and EPTB; smear+ and smear−)
Newman et al28 CSS (recruitment 
duration: 1 yr)
Positive placental blood smear 
defined as parasite density ≥1 
parasite/μL
HIV-infected and uninfected pregnant women
Nunn et al18 Range: 0-3.8 yrs of FU NA HIV-infected adults being treated for TB
Nunn et al19 FU duration: 2.5 yrs 
(participants were 
followed up for a 
minimum of 1 yr)
NA Women with HIV infection
WHO stage 2 or 3
Recent delivery
Pitter et al48 CE study CE study CE study
Polyak et al35 FU duration: 1 yr Malaria defined as rapid 
diagnostic test or smear 
positive with fever, 
pneumonia, and diarrhea 
(systematically ascertained)
HIV-infected adults who had been on ART for >18 
mo and had CD4 count >350/μL
Suthar et al39 SRM NA SRM
Van Oosterhout et al20 FU duration: 0.5 yrs NA ART-naive individuals aged 18 yrs or older initiating 
ART
Walker et al36 Median = 4.9 yrs “New WHO stage 4,” “new or 
recurrent WHO stage 3 or 4,” 
and malaria (“clinical” or 
“microscopic” diagnosis)
From the “DART randomized trial of management 
strategies in HIV-infected symptomatic (WHO stage 
2-4)”
Aged 18 yrs or older, starting ART
CD4 cell counts <200 cells/μL
No history of ART uptake (except PMTCT)
Watera et al37 Person-years of FU: 
1463 (before and after 
“Primary outcomes”: fever 
and “other clinical signs, and 
positive laboratory tests”
HIV-seropositive adults (aged older than 15 yrs)
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CTX prophylaxis 
introduction)
“Less well-defined morbid 
events” (secondary outcomes): 
clinical signs without 
laboratory tests results
Wiktor et al38 Median = 0.87 Morbidity assessed through 
“hospital admission rates”
HIV 1 infection and (HIV 1 and HIV 2) infected 
clients. “Sputum smear-positive PTB”
Yazdanpanah et al49 CE study CE study CE study
Zachariah et al21 FU duration: 1 yr NA HIV-infected TB patients
CTX, cotrimoxazole; DALY, disability adjusted life-years; DART, Development of Anti-Retroviral Therapy; EPTB, extra-pulmonary tuberculosis; 
FU, follow-up; PTB, pulmonary tuberculosis; TB, tuberculosis; WHO, World Health Organization.
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